Human Genome Sciences (HGSI)
News
| 4:32 PM | $HGSI what are thoughts on this one? by lilputian |
| May 27 | $ILMN? $GNOM $LIFE $PACB $CGEN $HGSI $SQNM by proper |
| May 25 | Which genomics co. Is Roche expected to bid for after getting denied by $ILMN? $GNOM $LIFE $PACB $CGEN $HGSI $SQNM other? by epime7heus |
| May 25 | Benzinga's Top Pre-Market Losers Benzinga |
| May 25 | @Glopolon I think I'll wait a bit more on $SPPI. Hope it doesn't run away from me like $HGSI did. by mitrado |
| May 25 | @GPrime $ARNA You could do what GSK is trying to do with $HGSI and buy if and when the share price falls back down again by SlownSteady |
| May 24 | genomics have been running for awhile now since $HGSI news and now $ROSG. $ILMN denied Roche buyout but who r next most likely targets? by epime7heus |
| May 24 | IV30(TM) GAINER $EMC +17.94% $CI +13.48% $AGP +12.73% $XLF +12.61% $HGSI +12.25% $RIMM +12.11% $TXN +12.08% $FFIV +11.54% $VMW +10.81% by livevol_pro |
| May 24 | Notable Analyst Rating Changes 05/24: (PPG) (WPI) (DUK) Upgraded; (BHI) (HGSI) (COG) ... |
| May 24 | IV30(TM) GAINER $GR +37.63% $EMC +14.7% $AMLN +7.51% $VMW +7.36% $FFIV +6.87% $HGSI +6.45% $RIMM +5.56% $OVTI +5.2% by livevol_pro |
| May 24 | BMO Capital Downgrades Human Genome Sciences (HGSI) to Market Perform Street Insider |
| May 24 | Benzinga's Top Downgrades Benzinga |
| May 23 | Greece Steals the Dow's Lunch Money Fool |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Biotechnology
Human Genome Sciences is a biopharmaceutical corporation founded in 1992. It uses the human DNA sequence to develop protein and antibody drugs. As of 2008, it has drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. It collaborates with other biotechnology and pharmaceutical companies, for development partnerships and licensing. The company was founded by William A. Haseltine, a noted Harvard professor and AIDS researcher. In late 2004, HGS announced Haseltine's retirement and named H. Thomas Watkins the new President and CEO. Human Genome Sciences, Inc. is headquartered in Rockville, Maryland.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Human Genome Sciences is down 48.76% over the last year vs S&P 500 Total Return up 1.18%, GlaxoSmithKline up 7.76%, and Amylin Pharmaceuticals up 109.8%.
- HGSI Total Returns
- ^SPXTR Total Returns
- GSK Total Returns
- AMLN Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these HGSI related companies
Pro Strategies Featuring HGSI
Did Human Genome Sciences make it into our Pro Portfolio Strategies?
HGSI Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other HGSI Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HGSI | 13.81 | +0.20 | +1.47% | 2.708B |
| HGSH | 0.70 | -0.08 | -10.26% | 31.54M |
| HGR | 22.05 | +0.69 | +3.23% | 727.09M |
| HGIC | 59.94 | +0.00 | +0.00% | 1.635B |
| HGI | 15.41 | +0.18 | +1.20% | |
| HGG | 11.09 | +0.22 | +2.02% | 404.80M |
| HGEM | 17.67 | +0.00 | +0.00% | |
| HFWA | 13.77 | +0.34 | +2.53% | 207.76M |
| HFC | 30.34 | +0.00 | +0.00% | 6.318B |
| HFBC | 7.05 | -0.10 | -1.47% | 55.62M |
